Conferences - Results from #60

ASCO 2023: Phase I/II Randomized Clinical Trial of In-Clinic Acupuncture Prior to BCG in Patients with High-Risk Non-Muscle Invasive Bladder Cancer June 3, 2023

ASCO 2023: Survival Outcomes in Patients with Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles June 3, 2023

ASCO 2023: Real-World Outcomes Among Patients with Advanced/metastatic RCC Treated with Cabozantinib or Other TKIs After Checkpoint Inhibitor Therapy June 3, 2023

ASCO 2023: EV-103: Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients with MIBC: Updated Results for Cohort H June 3, 2023

ASCO 2023: ENLIGHTED: A Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Padeliporfin Vascular Targeted Photodynamic Therapy in Treatment of Low-Grade UTUC June 3, 2023

ASCO 2023: Age, Sex, and Race-Related Differences in Outcomes of Patients with Muscle-Invasive Bladder Cancer Treated with Radical Cystectomy: The Role of Biology Versus Access to Standard Medical Care June 3, 2023

ASCO 2023: Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy: Updated Individual Patient Data Meta-Analyses from the MARCAP Consortium June 3, 2023

ASCO 2023: KEYNOTE-905/EV-303: A Phase 3 Study to Evaluate the Efficacy and Safety of Perioperative Pembrolizumab or Pembrolizumab + Enfortumab Vedotin for MIBC June 3, 2023

ASCO 2023: Basal-Luminal Subtyping of Localized High-Risk Prostate Cancer and Benefit of Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase III Trial June 3, 2023

ASCO 2023: Post Radical Prostatectomy PSA Outcomes Following 6 vs 18 Months of Perioperative Androgen Deprivation Therapy in Men with Localized High Risk Prostate Cancer: Results of Part 2 of a Randomized Phase 2 Trial June 3, 2023

ASCO 2023: Depth of PSA Nadir and Subsequent PSA Progression-Free Survival in Patients with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO Study (AFT-19) June 3, 2023

ASCO 2023: Assessing Racial Differences in Time to Treatment Escalation Following Androgen-Deprivation Therapy Among Veterans with Prostate Cancer June 3, 2023

ASCO 2023: CABIOS Trial: A Phase Ib Study of Cabozantinib and Nivolumab in Combination with Abiraterone in Patients with Metastatic Hormone Sensitive Prostate Cancer June 3, 2023

ASCO 2023: Darolutamide Observational (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Second Interim Analysis. June 3, 2023

ASCO 2023: Landscape and Impact of Germline Pathogenic Variants in Metastatic Hormone Sensitive Prostate Cancer: Ancillary Study of E3805 CHAARTED June 3, 2023

ASCO 2023: Prostate-Specific Antigen Value at 3 & 7 Months (PSA-3mo, PSA-7mo) and Overall Survival (OS) in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation (ADT) with or without Orteronel (SWOG S1216) June 3, 2023

ASCO 2023: EV-104: A First-in-Human Trial of Intravesical Enfortumab Vedotin, an Antibody-Drug Conjugate, in Patients with NMIBC: Interim Results of a Phase 1 Study June 3, 2023

ASCO 2023: Health-Related Quality of Life Measures in RCC: Patient-Reported Relevance of Items of the FKSI-19, EORTC QLQ-C30, and EQ-5D June 3, 2023

ASCO 2023: Enzalutamide, Docetaxel and Androgen Deprivation (ENZADA Trial) for Metastatic Castrate Sensitive Prostate Cancer June 3, 2023

ASCO 2023: Circulating Tumor Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Treated with Olaparib plus 177lutetium-Prostate Specific Membrane Antigen-617 (177Lu-PSMA-617) in the LuPARP Trial June 3, 2023

Page 4 of 520